Outlook Therapeutics (NASDAQ:OTLK) Now Covered by Analysts at Chardan Capital

Investment analysts at Chardan Capital initiated coverage on shares of Outlook Therapeutics (NASDAQ:OTLKGet Rating) in a note issued to investors on Tuesday, September 13th, MarketBeat.com reports. The firm set a “buy” rating on the stock.

Separately, Ascendiant Capital Markets decreased their price objective on Outlook Therapeutics to $7.00 in a research report on Monday, August 22nd.

Outlook Therapeutics Stock Performance

Shares of OTLK traded down $0.02 during midday trading on Tuesday, hitting $1.24. The stock had a trading volume of 598,807 shares, compared to its average volume of 1,042,930. The business has a 50-day simple moving average of $1.16 and a two-hundred day simple moving average of $1.39. Outlook Therapeutics has a fifty-two week low of $0.68 and a fifty-two week high of $2.40.

Outlook Therapeutics (NASDAQ:OTLKGet Rating) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). On average, equities research analysts expect that Outlook Therapeutics will post -0.29 earnings per share for the current year.

Hedge Funds Weigh In On Outlook Therapeutics

Hedge funds have recently modified their holdings of the stock. ProShare Advisors LLC grew its stake in Outlook Therapeutics by 70.5% in the fourth quarter. ProShare Advisors LLC now owns 19,461 shares of the company’s stock valued at $26,000 after purchasing an additional 8,050 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in Outlook Therapeutics by 174.2% in the second quarter. BNP Paribas Arbitrage SA now owns 25,837 shares of the company’s stock worth $26,000 after buying an additional 16,414 shares during the last quarter. Flower City Capital acquired a new stake in Outlook Therapeutics in the first quarter valued at approximately $36,000. Envestnet Asset Management Inc. bought a new stake in Outlook Therapeutics in the fourth quarter worth approximately $50,000. Finally, Principal Financial Group Inc. increased its stake in shares of Outlook Therapeutics by 92.8% during the 4th quarter. Principal Financial Group Inc. now owns 36,686 shares of the company’s stock worth $50,000 after purchasing an additional 17,661 shares during the last quarter. 11.71% of the stock is owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

(Get Rating)

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Featured Articles

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.